For the first time in as long as I can remember, IPOs dominated the New England tech and life sciences deals news this week.
—Glasshouse Technologies, an IT consulting firm in Framingham, MA, indicated in an SEC filing that it’s planning an initial public offering worth as much as $75 million. Glasshouse, which is aiming to trade on the New York Stock Exchange under the ticker symbol GLAS, had abandoned a previous attempt to go public back in March 2009.
—BG Medicine also revived its IPO ambitions this week, after nixing an $80 million offering in January 2008. The Waltham, MA-based developer of molecular diagnostics is now proposing to raise as much as $86.3 million to help bring its test for heart failure to market in the U.S. and Europe.
—The much-anticipated initial public offering from Cambridge, MA-based Ironwood Pharmaceuticals (NASDAQ: IRWD) priced below its proposed range of $14 to $16 per share on Tuesday, with 16.67 million shares going for $11.25 apiece. The stock’s price climbed modestly on its first day of trading, closing the day up 3.6 percent at $11.65.
—In non-IPO news, Westford, MA-based BioBehavioral Diagnostics raised $10 million in a Series B financing led by Sevin Rosen Funds and Tullis Dickerson. The startup intends to use the funds in part to expand sales and marketing efforts for a system used to diagnose attention-deficit hyperactivity disorder.
—Software maker Vivox of Natick, MA, raised $6.8 million in a third round of venture financing led by new investor IDG Ventures SF and joined by return investors Benchmark Capital, Canaan Partners, and GrandBanks Capital. Vivox’s technology allows gamers and inhabitants of virtual worlds such as Second Life, EVE Online, and EverQuest to talk with each other over the Internet.
—Robotics startup CyPhy Works raised $1.75 million in a round of equity financing, according to an SEC filing. The Cambridge-based startup is led by iRobot co-founder Helen Greiner.
—Lexington, MA-based 1366 Technologies, a developer of more efficient photovoltaic panels, nabbed $5.2 million in a Series B financing round, according the company’s president, Frank van Mierlo. North Bridge Venture Partners and Polaris Venture Partners provided $5 million of the funds and members of 1366’s management provided the rest, van Mierlo said.
—Cancer therapy developer Syndax Pharmaceuticals of Waltham collected $9 million of a planned $16 million in an offering of equity, options, and warrants, according to regulatory filings.
—Newton, MA-based Powerhouse Dynamics, a developer of home energy usage monitoring tools, closed a $1.02 million financing round. The deal was led by Lexington-based CommonAngels.
—Tepha, a Lexington-based maker of polymers for medical applications spun off by Cambridge-based Metabolix (NASDAQ:MBLX), raised $3 million in an equity financing, according to an SEC filing. The deal could eventually total $7.4 million, the filing indicates.